Stevanato Group S.p.A. (STVN) News
Filter STVN News Items
STVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STVN News Highlights
- STVN's 30 day story count now stands at 2.
- Over the past 26 days, the trend for STVN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about STVN are SMID.
Latest STVN News From Around the Web
Below are the latest news stories about STEVANATO GROUP SPA that investors may wish to consider to help them evaluate STVN as an investment opportunity.
What Makes Stevanato Group S.p.A. (STVN) a Worthy Stock?TimesSquare Capital Management, an equity investment management company, released its “U.S. SMID Cap Growth Strategy” third-quarter investor letter. The same can be downloaded here. In the third quarter, the U.S. SMID Cap Growth Composite fell -2.65% (gross) and -2.89% (net) compared to the Russell 2500 Growth Index’s -6.84% decline. This quarter, the small-to-mid-cap growth stocks […] |
Will Stevanato Group S.p.A. (STVN) be Able to Drive Attractive Earnings Growth?Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned -7.98%, Advisor Class fund APDSX posted a return of -7.96%, and Institutional Class fund APHSX returned -7.97%, compared to a […] |
Stevanato Group's Mavis™ Combi Visual Inspection Machine Selected as Pharma Innovation Award Winner by Pharma ManufacturingPIOMBINO DESE, Italy, November 16, 2023--Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, announced today that its Mavis™ Combi visual inspection machine has been selected as a winner of the 2023 Pharma Innovation Awards by Pharma Manufacturing, a brand of Endeavor Business Media. |
Stevanato Group to Present at the Jefferies London Healthcare ConferencePIOMBINO DESE, Italy, November 09, 2023--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Jefferies London Healthcare Conference taking place from November 14, 2023 to November 16, 2023. |
Stevanato Group S.p.A. (NYSE:STVN) Q3 2023 Earnings Call TranscriptStevanato Group S.p.A. (NYSE:STVN) Q3 2023 Earnings Call Transcript October 31, 2023 Operator: Good afternoon. This is the Chorus Call conference operator. Welcome and thank you for joining the Stevanato Group Third Quarter 2023 Financial Results Conference Call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity […] |
Stevanato Group (STVN) Q3 Earnings Meet EstimatesStevanato (STVN) delivered earnings and revenue surprises of 0% and 3.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Stevanato Group Reports Third Quarter 2023 Financial ResultsPIOMBINO DESE, Italy, October 31, 2023--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2023. |
TAK vs. STVN: Which Stock Is the Better Value Option?TAK vs. STVN: Which Stock Is the Better Value Option? |
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseAkebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings GrowthStevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |